# Evaluation of Safety and Effectiveness of the EMBLOK EPS During TAVR

Study · id `cardio:ct-nct05295628` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05295628](<https://clinicaltrials.gov/study/NCT05295628>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05295628

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 532 participants.

## Technical summary

Registry record NCT05295628. Randomized; double masking; primary purpose prevention. Start 2023-10-17 (actual); primary completion 2025-05-06 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose prevention
- Phase: Not applicable
- Enrolled: 532 participants (planned count; ClinicalTrials.gov record NCT05295628, source copy `cardio:ctgov-nct05295628-2025-08-06`, retrieved 2026-10-26)
- Started: 2023-10-17 (actual) (ClinicalTrials.gov record NCT05295628, source copy `cardio:ctgov-nct05295628-2025-08-06`, retrieved 2026-10-26)
- Primary completion: 2025-05-06 (actual) (ClinicalTrials.gov record NCT05295628, source copy `cardio:ctgov-nct05295628-2025-08-06`, retrieved 2026-10-26)
- Completion: 2025-10-01 (anticipated) (ClinicalTrials.gov record NCT05295628, source copy `cardio:ctgov-nct05295628-2025-08-06`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT05295628, source copy `cardio:ctgov-nct05295628-2025-08-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05295628-2025-08-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluation of Safety and Effectiveness of the EMBLOK EPS During TAVR
- Condition: Aortic Valve Stenosis
- Condition: Aortic Valve Disease
- Condition: Aortic Valve Insufficiency
- Condition: Aortic Valve Replacement
- Intervention (Device): EMBLOK™ Embolic Protection System ("EMBLOK EPS")
- Intervention (Device): SENTINEL™ Cerebral Protection System
- Lead sponsor: Emblok, Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: Yale Cardiovascular Research Group
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Aortic regurgitation (`cardio:aortic-regurgitation`)
- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as a collaborator: Yale Cardiovascular Research Group (`cardio:org-yale-cardiovascular-research-group`)

## Provenance

Content hash: c2e49a8b351ac8d2b1c97cd5b8b196bba2b2d524d439a85a8105b44f8390e01e
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
